Seres Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Seres Therapeutics

02/11/2023 13:33

* Seres Therapeutics Inc  MCRB.OQ  reported a quarterly
adjusted
loss of 37 cents​​ per share for the quarter ended in September,
higher than the same quarter last year, when the company
reported EPS of -49 cents.  The mean expectation of
seven analysts for the quarter was for a loss of 50 cents per
share. Wall Street expected results to range from -67 cents
to -38 cents per share.
    * Revenue rose 8,901.2% to $310.00 million from a year ago;
analysts expected $1.87 million. 
    * Seres Therapeutics Inc's reported EPS for the quarter was
a loss
of 37 cents​.
    * The company reported a quarterly loss of $47.85 million.
    * Seres Therapeutics Inc shares had fallen by 39.5% this
quarter and lost 74.3% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 16.9%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Seres
Therapeutics Inc is $11.00 
This summary was machine generated from LSEG data November 2 at
01:33 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.50          -0.37          Beat
 Jun. 30 2023      0.53           0.36           Missed
 Mar. 31 2023      -0.55          -0.57          Missed
 Dec. 31 2022      -0.46          -0.54          Missed